Skip to main content
micro-community-banner
 
  • Saved

Commented on 's Post

Accidental Ixazomib Overdose in a Patient With Multiple Myeloma - PubMed

Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33980053/

Show More Comments

  • 4 months
    Valuable piece as our best intended instructions don’t always “reach” the patient and while hopefully uncommon, this can be a resource for a practicing clinician
  • 4 months
    Please share your thoughts concerning overdose on oral chemotherapy.
  • Saved

made a Post

The Proximal Tubule Toxicity of Immunoglobulin Light Chains - PubMed

Plasma and B cells dyscrasias that overproduce monoclonal immunoglobulin free light chains (FLCs) affect the kidney frequently in various ways. The hematologic dyscrasia responsible for the production of FLCs may ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34013100/

  • Saved

made a Post

Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient - PubMed

Chimeric antigen receptor T (CAR-T)-cell therapy is a promising treatment for relapsed/refractory multiple myeloma (RRMM). In our previous report, CD19- and BCMA-targeted CAR-T co-administration was associated with a high response ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34009622/

  • Saved

made a Post

How to Treat High-Risk Myeloma at Diagnosis and Relapse - PubMed

Survival in multiple myeloma has improved greatly during the past 2 decades, but this change has primarily benefited patients who have standard-risk disease. Patients with high-risk disease remain a challenge ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34010042/

  • Saved

made a Post

When and How to Treat Relapsed Multiple Myeloma - PubMed

The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34010043/

  • Saved

made a Post

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab - PubMed

doi: 10.1038/s41408-021-00478-4. 1 Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA. 2 Unité Hémopathies Lymphoïdes, CHU Henri Mondor, Créteil, France. 3 Service d'hématologie, CHRU Hôpitaux de ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33980831/

  • Saved

made a Post

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma - PubMed

doi: 10.1186/s12859-021-04167-8. 1 Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, 410000, China. 2 Department of Blood Transfusion, The Seventh Affiliated Hospital of Sun Yat-Sen University, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33971811/

  • Saved

made a Post

Identification and Validation of a Novel RNA-Binding Protein-Related Gene-Based Prognostic Model for Multiple Myeloma - PubMed

doi: 10.3389/fgene.2021.665173. 1 Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China. 2 Department of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33981333/

  • Saved

made a Post

Prediction of High-Risk Cytogenetic Status in Multiple Myeloma Based on Magnetic Resonance Imaging: Utility of Radiomics and Comparison of Machine Learning Methods - PubMed

doi: 10.1002/jmri.27637. Online ahead of print. 1 Department of Radiology, Peking University Third Hospital, Haidian District, Beijing, People's Republic of China. 2 Huiying Medical Technology (Beijing) Co., Ltd, Beijing, China. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33979466/

  • Saved

made a Post

Multiple myeloma presenting as cryoglobulinemic vasculitis - PubMed

doi: 10.1016/j.jdcr.2021.03.026. 1 Medical School, University of Michigan, Ann Arbor, Michigan. 2 Ochsner Health Center, New Orleans, Louisiana. 3 Department of Pathology, University of Michigan, Ann Arbor, Michigan. 4 Division ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33948463/

  • Saved

made a Post

MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance - PubMed

Multiple myeloma (MM) is a common malignant hematological malignancy. Recently, interest has grown in the role of non-coding regions in disease pathogenesis. MicroRNAs (miRNAs) are small non-coding RNAs containing 19-25 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33949926/

  • Saved

made a Post

Evaluation of an open-source machine-learning tool to quantify bone marrow plasma cells - PubMed

doi: 10.1136/jclinpath-2021-207524. Online ahead of print. 1 Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada [email protected] 2 Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33952591/

  • Saved

made a Post

DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome - PubMed

DIS3 gene mutations (DIS3mts) occur in roughly 10% of multiple myeloma (MM) patients; furthermore, DIS3 expression could be affected by monosomy 13 or del(13q), which occur in approximately 40% of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33951891/

  • Saved

made a Post

Evaluation of an open-source machine-learning tool to quantify bone marrow plasma cells - PubMed

doi: 10.1136/jclinpath-2021-207524. Online ahead of print. 1 Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada [email protected] 2 Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33952591/

  • Saved

Commented on 's Post

Genetic Predictors of Mortality in Multiple Myeloma | TACG

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells. The disease is virtually always preceded by an asymptomatic stage named monoclonal gammopathy of undetermined ..... see more

Source : https://www.dovepress.com/genetic-predictors-of-mortality-in-patients-with-multiple-myeloma-peer-reviewed-fulltext-article-TACG

Show More Comments

  • 4 months 2 weeks
    This article is a nice review of genetic abnormalities associated with myeloma, yet much remains to be learned about the mechanisms of progression and varying rates of such complications
  • Saved

Commented on 's Post

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma - PubMed

doi: 10.3324/haematol.2020.277152. Online ahead of print. 1 Department of Medicine I, Wilhelminen Cancer Research Institute, Clinic Ottakring, Vienna, Austria; Recipient of a DOC Fellowship of the Austrian Academy of Sciences ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33910332/

Show More Comments

  • 4 months 2 weeks
    Will be interesting to see if this bench research on myeloma cell lines can be translated into a clinically useful combination strategy at the bedside
  • Saved

Commented on 's Post

Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma - PubMed

Patients with depression had a substantially high risk of poor adherence compared to patients without depression. Given that Rd treatment is mainly offered by outpatient clinics, active interventions to reduce ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33575840/

Show More Comments

  • 4 months 3 weeks
    Very important topic linking compliance and ultimately effectiveness of oral antineoplastic therapy with depression
  • Saved

Commented on 's Post

Clinical outcomes and complications of surgical interventions for multiple myeloma lesions in the extremities and pelvis: A retrospective clinical study - PubMed

Objective: This study aimed to assess the pain and functional status of patients who underwent various surgical interventions for the stabilization of selected multiple myeloma (MM) lesions in the extremities ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33847579/

Show More Comments

  • 5 months
    Location rather than the disease seems to best reflect the outcome of surgical intervention for skeletal related cancer complications
  • Saved

Commented on 's Post

Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients - PubMed

The global, randomized, open-label KEYNOTE-183 phase 3 study was closed early after an interim analysis showed unfavorable risk-benefit when pembrolizumab was added to pomalidomide and dexamethasone in patients with relapsed ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33856638/

Show More Comments

  • 5 months
    Small numbers in this retrospective analysis. At most hypothesis generating but seems unlikely that this will see additional work
  • Saved

Commented on 's Post

Bleeding Diathesis in Multiple Myeloma: A Rare Presentation of a Dreadful Emergency With Management Nightmare - PubMed

Multiple myeloma is a neoplastic disorder of plasma cells. An abnormal coagulation profile, though commonly seen in multiple myeloma, can rarely manifest as life-threatening hemorrhagic complications. Bleeding tendencies in multiple ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33880309/

Show More Comments

  • 5 months
    This is a case report of a very rare complication of a relatively common disease. Report reflects the fact that malignant hematologists sometimes have to work through complex benign hematological Show More